Board of Directors

Paul F. Truex

Independent Non-Executive Director

Mr. Truex founded LQT Therapeutics, a private pharmaceutical company focusing on the development of novel therapeutics to treat Long QT Syndrome. Previously Mr. Truex founded Anthera Pharmaceuticals, Inc., a previously publicly traded biopharmaceutical company, in September 2004 and served as the Executive Chairman of the board of directors of Anthera until December 2018. He previously served as the President of Anthera from its inception in September 2004 until January 2016 and as its Chief Executive Officer from September 2004 to December 2016. Prior to founding Anthera, Mr. Truex served as a founder, director, President and Chief Executive Officer of Peninsula Pharmaceuticals, Inc. from the commencement of its operations in October 2001 until December 2005 after which Peninsula was acquired in a series of transactions by Johnson and Johnson and Forest Laboratories. Mr. Truex is currently a director at CymaBay Therapeutics Inc., a Nasdaq-listed company, where he has served since April 2016. Mr. Truex is also a board member of Gladius Pharmaceuticals and Feldan Therapeutics, both private pharmaceutical companies.

Mr. Truex obtained an MBA in Marketing and Finance from Indiana University and a BA in Economics from the University of Waterloo.